The MISTRAL project is carrying out an observational study involving a European cohort to investigate how the gut microbiome influences the development and progression of both HIV-related and non-HIV-related diseases. The study is being led by the partner institution CHIP – Centre of Excellence for Health, Immunity, and Infections in Denmark. The primary focus of the study is to examine inflammatory markers, such as those linked to cardiovascular disease and thrombosis, along with broader metabolic and proteomic profiles.
Sample Collection and Sequencing
At the onset of the study, stool samples were collected from all participants, and the DNA from these samples was analysed to identify the microbes present in their gut. To date, researchers have completed the analysis of the first 500 DNA samples using advanced computational methods. The remaining samples are expected to be analysed in the coming months. The initial sequencing data have been validated for quality, ensuring the reliability of subsequent analyses.
Research Focus and Preliminary Findings
A comprehensive analysis plan has been developed, concentrating on three main areas:
- Associations between the gut microbiome and systemic inflammation
- Links between microbiome profiles and cardiovascular disease risk scores
- Connections between gut microbiota and cholesterol levels
Early results from the first 500 participants reveal strong links between differences in the gut microbiome and various clinical, behavioural, and demographic factors. Important factors include gender, the method of HIV transmission, sexual behaviours, and levels of inflammatory biomarkers.
Data Catalogue Development
In parallel, the team is developing a structured data catalogue to provide researchers with a clear overview of the various data types collected within the MISTRAL study, facilitating data sharing and collaboration.
